Booster shots for fully vaccinated Americans, Ebola in Ivory Coast

August 24, 2021

1 min read

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

”
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Starting Sept. 20, U.S. officials said that Americans will be able to receive a third dose of the Pfizer-BioNTech or Moderna mRNA vaccines 8 months after the date they received their second shot.

The announcement was the top story in infectious disease last week.

Source: Adobe Stock

Also, health officials in Africa said the Ivory Coast was in “full response mode” after a woman aged 18 years was diagnosed with Ebola. It is the first recorded case of Ebola in Ivory Coast since 1994.

Read these and more top stories in infectious disease below:

US to offer booster shots to fully vaccinated Americans starting Sept. 20

The United States will begin offering third doses of COVID-19 vaccine to fully vaccinated Americans beginning Sept. 20, Biden administration officials announced. Read more.

‘Immense concern’ over Ivory Coast’s first case of Ebola in decades

Heath officials expressed concern after Ivory Coast reported its first case of Ebola virus in decades. Read more.

Paratek receives orphan drug status for Nuzyra to treat NTM lung disease

The FDA granted Paratek Pharmaceuticals orphan drug designation for Nuzyra to treat infections caused by nontuberculous mycobacteria, the company announced. Read more.

WHO seeks experts for new advisory group on emerging pathogens

WHO issued a “call for experts” to join its new advisory group on emerging pathogens. Read more.

Nearly half of MSM taking HIV PrEP tested positive for gastrointestinal pathogens

In a small study, researchers detected gastrointestinal pathogens in 45% of men who have sex with men taking HIV PrEP, according to findings published in Open Forum Infectious Diseases. Read more.